Is ZNTL or EXOZ more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% eXoZymes N/A -220.63% -141.26%

Does the media prefer ZNTL or EXOZ?

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 2 articles in the media. eXoZymes' average media sentiment score of 1.19 beat Zentalis Pharmaceuticals' score of 0.93 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EXOZ or EDIT?

Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 68.75%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is EXOZ or EDIT more profitable?

eXoZymes has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. eXoZymes' return on equity of -220.63% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Editas Medicine -281.59% -677.39% -58.25%

Does the media prefer EXOZ or EDIT?

In the previous week, eXoZymes and eXoZymes both had 2 articles in the media. eXoZymes' average media sentiment score of 1.19 beat Editas Medicine's score of 0.93 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EXOZ or MGNX?

MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 13.17%. Given MacroGenics' stronger consensus rating and higher possible upside, analysts plainly believe MacroGenics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MacroGenics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Is EXOZ or MGNX more profitable?

eXoZymes has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% MacroGenics -44.79% -147.80% -28.40%

Do analysts prefer EXOZ or AVXL?

Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 720.51%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anavex Life Sciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is EXOZ or AVXL more profitable?

Anavex Life Sciences' return on equity of -38.76% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Anavex Life Sciences N/A -38.76% -35.01%

Does the media prefer EXOZ or AVXL?

In the previous week, eXoZymes and eXoZymes both had 2 articles in the media. eXoZymes' average media sentiment score of 1.19 beat Anavex Life Sciences' score of 0.93 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EXOZ or FBRX?

Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 214.26%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is EXOZ or FBRX more profitable?

Forte Biosciences' return on equity of -106.17% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Forte Biosciences N/A -106.17% -85.50%

eXoZymes (EXOZ) Competitors

$8.42 +0.39 (+4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$8.37 -0.05 (-0.59%)

As of 04:10 PM Eastern

Compare

EXOZ vs. ZNTL, EDIT, MGNX, AVXL, and FBRX

Should you buy eXoZymes stock or one of its competitors? MarketBeat compares eXoZymes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eXoZymes include Zentalis Pharmaceuticals (ZNTL), Editas Medicine (EDIT), MacroGenics (MGNX), Anavex Life Sciences (AVXL), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry.

How does eXoZymes compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Zentalis Pharmaceuticals' return on equity of -53.61% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
eXoZymes	N/A	-220.63%	-141.26%

Zentalis Pharmaceuticals presently has a consensus price target of $5.83, suggesting a potential upside of 26.54%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 2 articles in the media. eXoZymes' average media sentiment score of 1.19 beat Zentalis Pharmaceuticals' score of 0.93 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.66, meaning that its stock price is 166% more volatile than the broader market.

eXoZymes has lower revenue, but higher earnings than Zentalis Pharmaceuticals. eXoZymes is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.87	-$137.06M	-$1.73	N/A
eXoZymes	$70K	1,020.02	-$9.16M	-$1.14	N/A

Summary

Zentalis Pharmaceuticals beats eXoZymes on 6 of the 11 factors compared between the two stocks.

How does eXoZymes compare to Editas Medicine?

eXoZymes (NASDAQ:EXOZ) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

eXoZymes has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. eXoZymes' return on equity of -220.63% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Editas Medicine	-281.59%	-677.39%	-58.25%

Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 68.75%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

eXoZymes has a beta of 2.66, suggesting that its share price is 166% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

eXoZymes has higher earnings, but lower revenue than Editas Medicine. eXoZymes is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,020.02	-$9.16M	-$1.14	N/A
Editas Medicine	$40.52M	7.73	-$160.06M	-$1.23	N/A

In the previous week, eXoZymes and eXoZymes both had 2 articles in the media. eXoZymes' average media sentiment score of 1.19 beat Editas Medicine's score of 0.93 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

eXoZymes beats Editas Medicine on 8 of the 14 factors compared between the two stocks.

How does eXoZymes compare to MacroGenics?

eXoZymes (NASDAQ:EXOZ) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 13.17%. Given MacroGenics' stronger consensus rating and higher possible upside, analysts plainly believe MacroGenics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

96.9% of MacroGenics shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, eXoZymes had 1 more articles in the media than MacroGenics. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for MacroGenics. eXoZymes' average media sentiment score of 1.19 beat MacroGenics' score of 0.94 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Positive
MacroGenics	Positive

eXoZymes has higher earnings, but lower revenue than MacroGenics. eXoZymes is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,020.02	-$9.16M	-$1.14	N/A
MacroGenics	$149.50M	2.07	-$74.62M	-$1.10	N/A

eXoZymes has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

eXoZymes has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
MacroGenics	-44.79%	-147.80%	-28.40%

Summary

MacroGenics beats eXoZymes on 8 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Anavex Life Sciences?

eXoZymes (NASDAQ:EXOZ) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

eXoZymes has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Anavex Life Sciences' return on equity of -38.76% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Anavex Life Sciences	N/A	-38.76%	-35.01%

eXoZymes has higher revenue and earnings than Anavex Life Sciences. eXoZymes is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,020.02	-$9.16M	-$1.14	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

In the previous week, eXoZymes and eXoZymes both had 2 articles in the media. eXoZymes' average media sentiment score of 1.19 beat Anavex Life Sciences' score of 0.93 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 720.51%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

31.6% of Anavex Life Sciences shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Anavex Life Sciences beats eXoZymes on 7 of the 12 factors compared between the two stocks.

How does eXoZymes compare to Forte Biosciences?

eXoZymes (NASDAQ:EXOZ) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

eXoZymes has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market.

Forte Biosciences' return on equity of -106.17% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Forte Biosciences	N/A	-106.17%	-85.50%

Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 214.26%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

eXoZymes has higher revenue and earnings than Forte Biosciences. eXoZymes is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,020.02	-$9.16M	-$1.14	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

77.6% of Forte Biosciences shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, eXoZymes had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat eXoZymes' score of 1.19 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
eXoZymes	Positive
Forte Biosciences	Very Positive

Summary

Forte Biosciences beats eXoZymes on 8 of the 13 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$68.09M	$3.65B	$6.84B	$12.43B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	N/A	21.29	25.83	24.36
Price / Sales	1,020.02	195.79	511.51	84.16
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	21.05	8.71	10.98	6.49
Net Income	-$9.16M	$23.87M	$3.57B	$336.61M
7 Day Performance	2.93%	4.23%	3.06%	0.90%
1 Month Performance	-12.11%	1.71%	0.72%	-0.36%
1 Year Performance	-18.96%	69.92%	36.82%	31.26%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.9161 of 5 stars	$8.42 +4.9%	N/A	-24.1%	$68.09M	$70K	N/A	29	Positive News High Trading Volume
ZNTL Zentalis Pharmaceuticals	2.5314 of 5 stars	$3.70 flat	$5.83 +57.7%	+242.4%	$263.39M	$67.43M	N/A	160
EDIT Editas Medicine	2.6586 of 5 stars	$2.69 flat	$5.40 +100.7%	+25.0%	$263.37M	$38.69M	N/A	230
MGNX MacroGenics	1.9295 of 5 stars	$4.13 flat	$5.50 +33.2%	+303.9%	$262.52M	$149.50M	N/A	430	Gap Down
AVXL Anavex Life Sciences	2.464 of 5 stars	$2.73 flat	$21.33 +681.4%	-72.4%	$253.00M	N/A	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. ZNTL, EDIT, MGNX, AVXL, and FBRX

How does eXoZymes compare to Zentalis Pharmaceuticals?

Summary

How does eXoZymes compare to Editas Medicine?

Summary

How does eXoZymes compare to MacroGenics?

Summary

How does eXoZymes compare to Anavex Life Sciences?

Summary

How does eXoZymes compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. ZNTL, EDIT, MGNX, AVXL, and FBRX

How does eXoZymes compare to Zentalis Pharmaceuticals?

Is ZNTL or EXOZ more profitable?

Do analysts recommend ZNTL or EXOZ?

Does the media prefer ZNTL or EXOZ?

Which has more volatility and risk, ZNTL or EXOZ?

Which has stronger valuation and earnings, ZNTL or EXOZ?

Summary

How does eXoZymes compare to Editas Medicine?

Is EXOZ or EDIT more profitable?

Do analysts rate EXOZ or EDIT?

Which has more volatility & risk, EXOZ or EDIT?

Which has stronger valuation & earnings, EXOZ or EDIT?

Does the media prefer EXOZ or EDIT?

Do institutionals & insiders hold more shares of EXOZ or EDIT?

Summary

How does eXoZymes compare to MacroGenics?

Do analysts recommend EXOZ or MGNX?

Do institutionals and insiders hold more shares of EXOZ or MGNX?

Does the media prefer EXOZ or MGNX?

Which has better earnings and valuation, EXOZ or MGNX?

Which has more volatility and risk, EXOZ or MGNX?

Is EXOZ or MGNX more profitable?

Summary

How does eXoZymes compare to Anavex Life Sciences?

Which has more volatility and risk, EXOZ or AVXL?

Is EXOZ or AVXL more profitable?

Which has higher valuation and earnings, EXOZ or AVXL?

Does the media prefer EXOZ or AVXL?

Do analysts prefer EXOZ or AVXL?

Do institutionals & insiders believe in EXOZ or AVXL?

Summary

How does eXoZymes compare to Forte Biosciences?

Which has more risk and volatility, EXOZ or FBRX?

Is EXOZ or FBRX more profitable?

Do analysts recommend EXOZ or FBRX?

Which has stronger valuation and earnings, EXOZ or FBRX?

Do institutionals and insiders have more ownership in EXOZ or FBRX?

Does the media favor EXOZ or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools